Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study

Seymur Gahramanov, Ahmed M Raslan, Leslie L Muldoon, Bronwyn E Hamilton, William D Rooney, Csanad G Varallyay, Jeffrey M Njus, Marianne Haluska, Edward A Neuwelt, Seymur Gahramanov, Ahmed M Raslan, Leslie L Muldoon, Bronwyn E Hamilton, William D Rooney, Csanad G Varallyay, Jeffrey M Njus, Marianne Haluska, Edward A Neuwelt

Abstract

Purpose: We evaluated dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging (DSC-MRI) using gadoteridol in comparison to the iron oxide nanoparticle blood pool agent, ferumoxytol, in patients with glioblastoma multiforme (GBM) who received standard radiochemotherapy (RCT).

Methods and materials: Fourteen patients with GBM received standard RCT and underwent 19 MRI sessions that included DSC-MRI acquisitions with gadoteridol on Day 1 and ferumoxytol on Day 2. Relative cerebral blood volume (rCBV) values were calculated from DSC data obtained from each contrast agent. T1-weighted acquisition post-gadoteridol administration was used to identify enhancing regions.

Results: In seven MRI sessions of clinically presumptive active tumor, gadoteridol-DSC showed low rCBV in three and high rCBV in four, whereas ferumoxytol-DSC showed high rCBV in all seven sessions (p = 0.002). After RCT, seven MRI sessions showed increased gadoteridol contrast enhancement on T1-weighted scans coupled with low rCBV without significant differences between contrast agents (p = 0.9). Based on post-gadoteridol T1-weighted scans, DSC-MRI, and clinical presentation, four patterns of response to RCT were observed: regression, pseudoprogression, true progression, and mixed response.

Conclusion: We conclude that DSC-MRI with a blood pool agent such as ferumoxytol may provide a better monitor of tumor rCBV than DSC-MRI with gadoteridol. Lesions demonstrating increased enhancement on T1-weighted MRI coupled with low ferumoxytol rCBV are likely exhibiting pseudoprogression, whereas high rCBV with ferumoxytol is a better marker than gadoteridol for determining active tumor. These interesting pilot observations suggest that ferumoxytol may differentiate tumor progression from pseudoprogression and warrant further investigation.

Conflict of interest statement

Conflict of Interest

The authors have no conflict of interest. There is a sponsored research agreement to OHSU from AMAG Pharmaceuticals.

Copyright © 2011 Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Regression after radiochemotherapy (RCT) (Patient #1 in Table 1). (A, E, I) T1-weighted magnetic resonance imaging (MRI) before and (B, F, J) after gadoteridol (Gd) administration. (A, B) MRI after surgery but before RCT demonstrates area of enhancement in the right temporal lobe (arrow). Relative cerebral blood volume (rCBV) in the enhancing area was lower on the Gd-rCBV parametric map (C) compared to the ferumoxytol (Fe)-rCBV map (D) (bold arrow). (E, F) MRI after completion of RCT revealed decreased enhancement (F, arrow) with low rCBV on Gd-rCBV (G) and Fe-rCBV parametric maps (H) (arrow). (I, J) MRI 14 months after completion of RCT showed resolution of enhancement. (K) First-pass time-intensity curves of the perfusions C and D demonstrate post-bolus increasing signal above the baseline when Gd was used while ferumoxytol post-bolus signal intensity was below the baseline and remains stable.
Figure 2
Figure 2
Pseudoprogression followed by true tumor progression (Patient #2 in Table 1). (A, C, G, I) T1-weighted magnetic resonance imaging (MRI) before and (B, D, H, J) after gadoteridol (Gd). (A, B) MRI after surgery but before radiochemotherapy (RCT) demonstrates residual enhancement (arrow). (C, D) MRI 2 months after RCT shows increased area of enhancement with low relative cerebral blood volume (rCBV) on both Gd (E) and ferumoxytol (Fe) parametric maps (F) (arrow). (G, H) Adjuvant temozolomide treatment was continued and enhancement decreased on MRI 25 months after the end of RCT (arrow). (I, J) Area of increased enhancement on MRI 28 months after RCT (arrow) coincided with high Fe-rCBV (L) and low Gd-rCBV (K) (bold arrows).
Figure 3
Figure 3
Mixed response to radiochemotherapy (RCT) (Patient #14 in Table 1). (A) T1-weighted contrast enhanced magnetic resonance imaging (MRI) before surgery demonstrated glioblastoma multiforme lesion which decreased in size after surgery (B). (C) MRI 1 month after RCT showed increased enhancement, with low relative cerebral blood volume (rCBV) within the lesion and a thin rim of high rCBV with ferumoxytol (Fe) and lower with gadoteridol (Gd) (D) (E) (arrow).
Figure 4
Figure 4
Comparison of relative cerebral blood volume (rCBV) acquired by dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) using ferumoxytol versus gadoteridol. Rapidly growing tumors are assocated with rCBV > 1.75 , indicated by the starred arrows. The rCBV obtained using gadoteridol was always lower than using ferumoxytol in tumor (P=0.002) and the mixed response group (P=0.007), but there was no difference between contrast agents in the pseudoprogression group (P=0.9).
Figure 5
Figure 5
Comparison of relative cerebral blood volume (rCBV) between tumor, pseudoprogression and mixed response groups. (A) Dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) using ferumoxytol revealed high rCBV in the tumor group (> 4.2), low in the pseudoprogression group ( 1.75, indicated by the starred arrows. (B) DSC-MRI using gadoteridol showed low rCBV (

Figure 6

Algorithm of evaluation and classification…

Figure 6

Algorithm of evaluation and classification of response to radiochemotherapy by conventional magnetic resonance…

Figure 6
Algorithm of evaluation and classification of response to radiochemotherapy by conventional magnetic resonance imaging (MRI) using gadolinium-based contrast agent and dynamic susceptibility contrast MRI using ferumoxytol.
Figure 6
Figure 6
Algorithm of evaluation and classification of response to radiochemotherapy by conventional magnetic resonance imaging (MRI) using gadolinium-based contrast agent and dynamic susceptibility contrast MRI using ferumoxytol.

References

    1. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–461.
    1. Chaskis C, Neyns B, Michotte A, et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. 2009
    1. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81–83.
    1. Tofilon PJ, Fike JR. The radioresponse of the central nervous system: a dynamic process. Radiat Res. 2000;153:357–370.
    1. Wong CS, Van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv. 2004;4:273–284.
    1. Nordal RA, Nagy A, Pintilie M, et al. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res. 2004;10:3342–3353.
    1. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 2008;10:361–367.
    1. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–2197.
    1. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994;191:41–51.
    1. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology. 1999;211:791–798.
    1. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol. 1998;171:1479–1486.
    1. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected] AJNR Am J Neuroradiol. 2004;25:214–221.
    1. Cao Y, Tsien CI, Nagesh V, et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected] Int J Radiat Oncol Biol Phys. 2006;64:876–885.
    1. Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008;247:170–178.
    1. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490–498.
    1. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. 2004;19:546–554.
    1. Barajas RF, Jr, Chang JS, Segal MR, et al. Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology. 2009
    1. Hoefnagels FW, Lagerwaard FJ, Sanchez E, et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol. 2009;256:878–887.
    1. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2009;30:552–558.
    1. Sorensen AG. Perfusion MR imaging: moving forward. Radiology. 2008;249:416–417.
    1. Neuwelt EA, Varallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery. 2007;60:601–611. discussion 611-602.
    1. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab. 2009;29:853–860.
    1. Weinstein J, Varallyay CG, Dosa E, et al. Superparamagnetic Iron Oxide Nanoparticles: Diagnostic Magnetic Resonance Imaging and Potential Therapeutic Applications in Neurooncology and CNS Inflammatory Pathologies, a Review. J Cereb Blood Flow Metab. 2009 In press.
    1. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14:1860–1869.
    1. Rachinger W, Goetz C, Popperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505–511. discussion 505–511.
    1. Tsuyuguchi N, Takami T, Sunada I, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma. Ann Nucl Med. 2004;18:291–296.
    1. Cao Y, Sundgren PC, Tsien CI, et al. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol. 2006;24:1228–1235.
    1. Schlemmer HP, Bachert P, Herfarth KK, et al. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol. 2001;22:1316–1324.
    1. Schlemmer HP, Bachert P, Henze M, et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology. 2002;44:216–222.
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
    1. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. 2008;249:601–613.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren